| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 9, 2006
Accepted on August 22, 2006
Departments of Chemistryand Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana IL 61801
* To whom correspondence should be addressed. E-mail: jkatzene{at}uiuc.edu.
Posttranslational modifications of the estrogen receptor (ER) are emerging as important regulatory elements of cross talk between different signaling pathways. ER phosphorylation, in particular, has been implicated in the ligand-independent effects of ER and in tamoxifen resistance of breast tumors. In our studies, Western immunoblot analysis of endogenous ER in parental MCF-7 cells reveals specific, ligand-dependent phosphorylations at S118 and S167, with this ligand dependence being lost in tamoxifen-resistant, MCF-7 Her2/neu cells. Using highly purified components and sensitive fluorescence methods in an in vitro system, we show that phosphorylation by different kinases alters ER action through distinct mechanisms. Phosphorylation by Src and PKA increases affinity for estradiol (E2), whereas ER phosphorylation by MAPK decreases trans-hydroxytamoxifen (TOT) binding. Affinity of ER for the consensus estrogen response element is also altered by phosphorylation in a ligand-specific manner, with decrease in affinity of MAPK- and Src-phosphorylated ER in the presence of TOT. ER phosphorylation by MAPK, AKT or PKA increases recruitment of SRC3 receptor interaction domain to the DNA-bound receptor in the presence of E2. Taken together, these results suggest that ER phosphorylation alters receptor functions (ligand, DNA and coactivator binding), effecting changes that could lead to an increase in E2 agonism and a decrease in TOT antagonistic activity, reflecting changes encountered in tamoxifen resistance in endocrine therapy of breast cancer.
NURSA Molecule Pages Link:
This article has been cited by other articles:
 |
|
 |
|
  H. Yamashita, M. Nishio, T. Toyama, H. Sugiura, N. Kondo, S. Kobayashi, Y. Fujii, and H. Iwase Low phosphorylation of estrogen receptor {alpha} (ER{alpha}) serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer Endocr. Relat. Cancer, September 1, 2008; 15(3): 755 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Fenne, T. Hoang, M. Hauglid, J. V. Sagen, E. A. Lien, and G. Mellgren Recruitment of Coactivator Glucocorticoid Receptor Interacting Protein 1 to an Estrogen Receptor Transcription Complex Is Regulated by the 3',5'-Cyclic Adenosine 5'-Monophosphate-Dependent Protein Kinase Endocrinology, September 1, 2008; 149(9): 4336 - 4345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chen, T. Dang, R. D. Blind, Z. Wang, C. N. Cavasotto, A. B. Hittelman, I. Rogatsky, S. K. Logan, and M. J. Garabedian Glucocorticoid Receptor Phosphorylation Differentially Affects Target Gene Expression Mol. Endocrinol., August 1, 2008; 22(8): 1754 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Paulmurugan, A. Tamrazi, J. A. Katzenellenbogen, B. S. Katzenellenbogen, and S. S. Gambhir A Human Estrogen Receptor (ER){alpha} Mutation with Differential Responsiveness to Nonsteroidal Ligands: Novel Approaches for Studying Mechanism of ER Action Mol. Endocrinol., July 1, 2008; 22(7): 1552 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Long, M. Fan, R. M. Bigsby, and K. P. Nephew Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-{alpha}-dependent and estrogen receptor-{alpha}-independent mechanisms Mol. Cancer Ther., July 1, 2008; 7(7): 2096 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Hammoud, B. Tan, S. Badve, and R. M Bigsby Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma Endocr. Relat. Cancer, June 1, 2008; 15(2): 475 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Tan, X. Long, H. Nakshatri, K. P Nephew, and R. M Bigsby Striatin-3{gamma} inhibits estrogen receptor activity by recruiting a protein phosphatase J. Mol. Endocrinol., May 1, 2008; 40(5): 199 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Andre, R. Nahta, R. Conforti, T. Boulet, M. Aziz, L. X. H. Yuan, F. Meslin, M. Spielmann, G. Tomasic, L. Pusztai, et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer Ann. Onc., February 1, 2008; 19(2): 315 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. H. Ing, D. A. Massuto, and L. A. Jaeger Estradiol Up-regulates AUF1p45 Binding to Stabilizing Regions within the 3'-Untranslated Region of Estrogen Receptor {alpha} mRNA J. Biol. Chem., January 18, 2008; 283(3): 1764 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. De los Santos, O. Martinez-Iglesias, and A. Aranda Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells Endocr. Relat. Cancer, December 1, 2007; 14(4): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Weigel and N. L. Moore Steroid Receptor Phosphorylation: A Key Modulator of Multiple Receptor Functions Mol. Endocrinol., October 1, 2007; 21(10): 2311 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Grisouard, S. Medunjanin, A. Hermani, A. Shukla, and D. Mayer Glycogen Synthase Kinase-3 Protects Estrogen Receptor {alpha} from Proteasomal Degradation and Is Required for Full Transcriptional Activity of the Receptor Mol. Endocrinol., October 1, 2007; 21(10): 2427 - 2439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Schultz-Norton, K. A. Walt, Y. S. Ziegler, I. X. McLeod, J. R. Yates, L. T. Raetzman, and A. M. Nardulli The Deoxyribonucleic Acid Repair Protein Flap Endonuclease-1 Modulates Estrogen-Responsive Gene Expression Mol. Endocrinol., July 1, 2007; 21(7): 1569 - 1580. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
